Compugen 配当と自社株買い
配当金 基準チェック /06
Compugen配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-4.1%
バイバック利回り
| 総株主利回り | -4.1% |
| 将来の配当利回り | n/a |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
ナラティブ更新 • May 03
CGEN: Future Upside Will Rely On Sustained Long Term Execution Confidence
Analysts have maintained their $13.00 price target on Compugen, citing recent bullish initiation and supportive research as reasons to keep their outlook. This remains the case despite slight adjustments to assumptions for the discount rate, revenue growth, profit margin, and future P/E.ナラティブ更新 • Apr 07
CGEN: Future Upside Will Depend On Sustained Long Term Earnings Potential
Analysts maintained their target for Compugen at $13.00, citing updated assumptions that now reflect a slightly higher discount rate, a modestly weaker revenue growth outlook, a small reduction in expected profit margin, and a very large projected future P/E multiple. Valuation Changes Fair Value: Target remains at $13.00, with no change from the prior estimate.ナラティブ更新 • Mar 22
CGEN: Unchanged US$13 Fair Value Will Rely On Long Term Earnings
Analysts kept their $13.00 price target for Compugen unchanged, with only small tweaks to underlying inputs such as discount rate, revenue growth assumptions, profit margin, and very large future P/E expectations supporting the decision to maintain the prior valuation view. Valuation Changes Fair Value: $13.00 fair value is unchanged, signaling no revision to the overall price target level.ナラティブ更新 • Mar 06
CGEN: Royalty Monetization And Immuno Oncology Pipeline Will Drive Future Upside
Analysts have reiterated a $13.00 price target on Compugen, citing updated assumptions that include a slightly higher discount rate, a shift to an 11% revenue contraction, a lower profit margin near 12%, and a very large forward P/E estimate as the basis for their current stance. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, amending their 2018 exclusive license agreement to support Compugen's balance sheet and immuno oncology pipeline (Key Developments).
新しいナラティブ • Mar 03
Ovarian Trial Delays And Royalty Uncertainty Will Test This Long Runway Story
Catalysts About Compugen Compugen is a clinical stage immuno oncology company that uses a computational discovery engine to develop antibody based cancer therapies and out license assets to larger partners. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Feb 20
CGEN: Royalty Sale And Oncology Pipeline Will Support Future Upside
Analysts have kept their price target for Compugen steady at $13.00, citing relatively unchanged fair value assumptions alongside small tweaks to the discount rate, very large projected revenue growth and expected profit margins, as well as an updated future P/E estimate. What's in the News Compugen and MedImmune Limited, part of the AstraZeneca Group, signed Amendment Number 4 to their March 30, 2018 license agreement covering rilvegostomig, updating the economic terms of Compugen's royalty interest (Key Developments).ナラティブ更新 • Feb 06
CGEN: Royalty Monetization And Oncology Pipeline Will Drive Future Upside
Narrative Update on Compugen Analysts have kept their price target for Compugen steady at $13.00, citing only minor tweaks to assumptions around discount rate, very high projected revenue growth and profit margin that did not materially change their overall view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).ナラティブ更新 • Jan 23
CGEN: Future Upside Will Be Driven By Royalty Monetization Deal
Analysts have kept their fair value estimate for Compugen steady at $13.00, with only minor model tweaks to discount rates, revenue growth assumptions and future P/E, helping to refine rather than reset their overall price target view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from the cancer drug candidate rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).ナラティブ更新 • Jan 09
CGEN: Future Upside Will Be Driven By Expanded Immuno Oncology Partnerships
Analysts have maintained their price target for Compugen at $13.00. They cite updated assumptions for discount rates, revenue growth, profit margins and a very large future P/E multiple as the main factors supporting this unchanged view.ナラティブ更新 • Dec 14
CGEN: Future Revenue Trajectory Will Be Driven By Ongoing COM701 Program
Analysts have raised their price target on Compugen to 13.00 dollars from 13.00 dollars, citing sharply higher projected revenue growth, improved long term profit margins and a more favorable future earnings multiple, even after incorporating a slightly higher discount rate. What's in the News Pooled analysis of COM701 Phase 1 trials in 60 evaluable patients with platinum resistant ovarian cancer published as an abstract by the European Society of Medical Oncology, highlighting anti tumor activity and safety in heavily pre treated patients (ESMO abstract) Analysis details outcomes for patients deriving clinical benefit, including progression free survival data, and is based on data from prior COM701 studies in platinum resistant ovarian cancer (Company announcement) Additional year of follow up data on COM701 in platinum resistant ovarian cancer will be featured in an upcoming ESMO poster, expanding on the initial pooled findings (ESMO poster) Compugen estimates interim analysis results for the ongoing COM701 program to be available by year end 2026, guided by the anticipated enrollment rate (Company guidance) Valuation Changes Fair Value: Unchanged at 13.00 dollars per share, reflecting no revision to the base case price target.分析記事 • Oct 07
There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise
Compugen Ltd. ( NASDAQ:CGEN ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...分析記事 • Oct 02
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
ナラティブ更新 • Aug 08
AI And Immunotherapy Advances Will Define Oncology's Future
Upward revisions to Compugen's revenue growth and net profit margin forecasts have driven a notable increase in its consensus analyst price target, which has risen from $5.50 to $6.25. What's in the News Compugen dosed the first patient in a global randomized sub-trial (MAIA-ovarian), evaluating its potential first-in-class anti-PVRIG antibody COM701 as maintenance therapy for relapsed platinum sensitive ovarian cancer.分析記事 • May 25
Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically
One thing we could say about the analysts on Compugen Ltd. ( NASDAQ:CGEN ) - they aren't optimistic, having just made a...分析記事 • Apr 09
Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Compugen fair value estimate is US$1.77 Current share price of...分析記事 • Feb 26
Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 2.9x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...
新しいナラティブ • Jan 26
COM701 Trial Will Present Future Opportunities, But Competitive Risks Remain
Strategic advancements in drug development and partnerships could significantly bolster earnings and create opportunities in less competitive markets.分析記事 • Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 4.1x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...分析記事 • May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
Compugen Ltd. ( NASDAQ:CGEN ) just released its first-quarter report and things are looking bullish. The results were...分析記事 • May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
Compugen Ltd. ( NASDAQ:CGEN ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Key Insights Compugen's estimated fair value is US$3.61 based on 2 Stage Free Cash Flow to Equity Compugen's US$2.32...分析記事 • Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Despite an already strong run, Compugen Ltd. ( NASDAQ:CGEN ) shares have been powering on, with a gain of 26% in the...分析記事 • Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, Compugen...分析記事 • Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 12
Compugen appoints Alberto Sessa as CFO
Clinical-stage cancer immunotherapy company Compugen (NASDAQ:CGEN) on Monday said it had appointed Alberto Sessa as its CFO. The appointment follows the departure of previous CFO Ari Krashin in May. Sessa will join CGEN on Nov. 1, 2022, the company said. According to CGEN, Sessa has more than 30 years of industry experience and most recently served as acting CFO at several startups in the high-tech industry. CGEN stock flat in mid-day trading.Seeking Alpha • Aug 24
Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Compugen (NASDAQ:CGEN) said that the Japan Patent Office granted a new composition of matter and use patent covering its anti-PVRIG, COM701 and backup anti-PVRIG antibodies. The Japanese patent No. 2017-562952 is expected to expire not before 2036. The company noted that in pre-clinical studies, blockade of PVRIG — a novel immune checkpoint — by COM701 has shown potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. CGEN +1.57% to $1.29 premarket Aug. 24Seeking Alpha • Aug 03
Compugen Q2 2022 Earnings Preview
Compugen (NASDAQ:CGEN) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close. The consensus EPS Estimate is -$0.11 (flat Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward.分析記事 • Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
CEO Anat Cohen-Dayag has done a decent job of delivering relatively good performance at Compugen Ltd. ( NASDAQ:CGEN...決済の安定と成長
配当データの取得
安定した配当: CGENの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: CGENの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Compugen 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (CGEN) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Biotechs) | 2.5% |
| アナリスト予想 (CGEN) (最長3年) | n/a |
注目すべき配当: CGENは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: CGENは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: CGENの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: CGENが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/07 07:51 |
| 終値 | 2026/05/07 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Compugen Ltd. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Ling Wang | Chardan Capital Markets, LLC |
| Michael King | Citizens JMP Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |